InMode Reports Strong Q2 2025 Financial Results Amid Challenges

InMode ( (INMD) ) has issued an announcement.

On July 30, 2025, InMode Ltd. announced its financial results for the second quarter of 2025, reporting revenues of $95.6 million, an increase from $86.4 million in the same quarter of 2024. Despite facing macroeconomic challenges and cautious consumer behavior, the company maintained an 80% gross margin and achieved a net income of $26.7 million. InMode’s international sales, particularly in Europe, showed strong performance, offsetting some domestic challenges. The company is also involved in a securities class action lawsuit filed in February 2024, which remains pending. While the ongoing geopolitical situation in Israel has not materially affected operations, the company continues to monitor developments closely.

The most recent analyst rating on (INMD) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on InMode stock, see the INMD Stock Forecast page.

Spark’s Take on INMD Stock

According to Spark, TipRanks’ AI Analyst, INMD is a Outperform.

InMode’s robust financial performance is the strongest factor, supported by a healthy balance sheet and solid profitability. However, challenges such as declining revenues, reduced margins, and tariff impacts highlighted in the earnings call detract from the overall score. Technical indicators suggest a neutral to slightly bearish trend, and the valuation indicates potential undervaluation, which could attract value investors.

To see Spark’s full report on INMD stock, click here.

More about InMode

InMode Ltd. is a leading global provider of innovative medical technologies. The company focuses on developing and commercializing minimally invasive aesthetic medical products, with a significant market presence in the medical technology industry.

Average Trading Volume: 1,286,283

Technical Sentiment Signal: Sell

Current Market Cap: $1.01B

Learn more about INMD stock on TipRanks’ Stock Analysis page.